CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events

0

CRISPR THERAPEUTICS AG (NASDAQ:CRSP) Files An 8-K Other Events
Item 8.01. Other Events

On December7, 2017, CRISPR Therapeutics AG issued a press release announcing the submission of a Clinical Trial Application for CTX001 in ß-thalassemia. A copy of the press release is attached hereto as Exhibit 99.1 and is incorporated herein by reference.

Item 8.01. Financial Statements and Exhibits.

(d)Exhibits:


CRISPR Therapeutics AG Exhibit
EX-99.1 2 d504564dex991.htm EX-99.1 EX-99.1 EXHIBIT 99.1   CRISPR Therapeutics Submits First Clinical Trial Application for a CRISPR Gene-Edited Therapy,…
To view the full exhibit click here

About CRISPR THERAPEUTICS AG (NASDAQ:CRSP)

Crispr Therapeutics AG is a Switzerland-based gene-editing company. The Company focuses on the development of transformative gene-based medicines for serious diseases using its Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/Cas9 gene-editing platform. CRISPR/Cas9 can be programmed to cut, edit and correct disease-associated deoxyribonucleic acid (DNA) in a patient’s cell. The location at which the Cas9 molecular scissors cut the DNA to be edited is specified by guide ribonucleic acid (RNA), which is comprised of a crRNA component and a tracrRNA component, either individually or combined together as a single guide RNA. The Company has business operations in London, the United Kingdom, as well as research and development operations in Cambridge, the United States.

An ad to help with our costs